Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets

doi:10.1016/j.hbpd.2018.04.003

Abstract
Figure/Table
References (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Hepatic fibrosis is a pathological lesion, characterized by the progressive accumulation of extracellular matrix (ECM) in the perisinusoidal space and it is a major problem in chronic liver diseases. Phenotypic activation of hepatic stellate cells (HSC) plays a central role in the progression of hepatic fibrosis. Retardation of proliferation and clearance of activated HSCs from the injured liver is an appropriate therapeutic strategy for the resolution and treatment of hepatic fibrosis. Clearance of activated HSCs from the injured liver by autophagy inhibitors, proapoptotic agents and senescence inducers with the high affinity toward the activated HSCs may be the novel therapeutic strategy for the treatment of hepatic fibrosis in the near future.

Key words： Hepatic stellate cells Apoptosis Autophagy Senescence Extracellular matrix

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles in this journal by
	Ezhilarasan D
	Sokal E
	Najimi M

Cite this article:

Ezhilarasan D, Sokal E, Najimi M. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int 2018; 17(3): 192-197. DOI:10.1016/j.hbpd.2018.04.003

URL:

http://dx.doi.org/10.1016/j.hbpd.2018.04.003 OR http://www.hbpdint.com/EN/Y2018/V17/I3/192